董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James M. Jenkins | 男 | Director | 61 | 未披露 | 40.00 | 2026-07-01 |
| Susan Elliott | 女 | Chief Operating Officer and Director | 69 | 31.38万美元 | 2132.83 | 2026-07-01 |
| Teresa Bair | 女 | Director | 55 | 5.63万美元 | 40.00 | 2026-07-01 |
| Susan Elliott | 女 | Chief Operating Officer and Director | 69 | 未披露 | 未持股 | 2026-07-01 |
| Mark S. Miller | 男 | Chairman of the Board and Chief Executive Officer and Director | 74 | 37.05万美元 | 2120.28 | 2026-07-01 |
| Charles N. Ellis | 男 | Director | 73 | 5.63万美元 | 56.00 | 2026-07-01 |
| Joseph Sardano | 男 | Director | 73 | 5.63万美元 | 61.00 | 2026-07-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susan Elliott | 女 | Chief Operating Officer and Director | 69 | 31.38万美元 | 2132.83 | 2026-07-01 |
| Carlos Camozzi | 男 | Chief Medical Officer | 73 | 未披露 | 未持股 | 2026-07-01 |
| Susan Elliott | 女 | Chief Operating Officer and Director | 69 | 未披露 | 未持股 | 2026-07-01 |
| Mark S. Miller | 男 | Chairman of the Board and Chief Executive Officer and Director | 74 | 37.05万美元 | 2120.28 | 2026-07-01 |
| Jon S. Verbeck | 男 | Chief Financial Officer | 65 | 18.48万美元 | 21.00 | 2026-07-01 |
董事简历
中英对照 | 中文 | 英文- James M. Jenkins
-
James M. Jenkins，他是Harter Secrest & Emery LLP（一家位于纽约州西部地区的律师事务所）的合伙人。他主要专注于企业管治及一般公司法律事务，包括首次和二次公开募股，私募，并购和证券法律合规等方面。他在1989年作为合伙人加入OmniLit Acquisition Corp.。1997年1月1日，他被选举成为正式的合伙人。他自2001年起出任OmniLit Acquisition证券业务集团的负责人，并从2007年1月至2013年1月，成为公司OmniLit Acquisition管理委员会的成员。他在Virginia Military Institute获得了学士学位，并在West Virginia University College of Law获得了法学博士学位。
James M. Jenkins has served as Birchbiomed Inc.'s lead independent director since May 2026. Mr. Jenkins is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Mr. Jenkins has served as President and Chief Executive Officer of Lakeland Industries, Inc. (Nasdaq: LAKE) since June 2024 where he has also served as Executive Chairman since August 2023. Prior to his appointment as President and Chief Executive Officer of Lakeland, Mr. Jenkins was the General Counsel and Vice President of Corporate Development for Transcat, Inc. (Nasdaq: TRNS), a provider of calibration, repair, inspection and laboratory services, where he served as Transcat's chief risk officer and advised management and the board of directors over matters of corporate governance and securities law. He also led Transcat's acquisition strategy. He joined Transcat in September 2020. Prior to joining Transcat, he was a partner at Harter Secrest & Emery LLP, a regional law firm located in New York State. His practice focused in the areas of corporate governance, and general corporate law matters, including initial and secondary public offerings, private placements, mergers and acquisitions, and securities law compliance. Mr. Jenkins joined the firm in 1989 as an associate and was elected a partner effective January 1, 1997. He is a Chambers rated attorney and served as the Chair of the firm's Securities Practice Group from 2001 to 2020 and as a member of the firm's Management Committee from January 2007 to January 2013. From 2018 until September 2020, he served as the Partner in Charge of the firm's New York City office. Mr. Jenkins holds a B.A. from Virginia Military Institute and a J.D. from West Virginia University College of Law. Mr. Jenkins currently serves on the board of directors of Lakeland Industries. Mr. Jenkins previously served on the board of directors of Mars Acquisition Corp. until its acquisition by ScanTech AI Systems Inc. (Nasdaq: STAI) and OmniLit Acquisition Corp. from September 2021 to April 2023. Mr. Jenkins previously served on the board of directors of ScanTech AI Systems Inc., was a member of its audit (Chair) and compensation committees, from December 2024 to October 2025. - James M. Jenkins，他是Harter Secrest & Emery LLP（一家位于纽约州西部地区的律师事务所）的合伙人。他主要专注于企业管治及一般公司法律事务，包括首次和二次公开募股，私募，并购和证券法律合规等方面。他在1989年作为合伙人加入OmniLit Acquisition Corp.。1997年1月1日，他被选举成为正式的合伙人。他自2001年起出任OmniLit Acquisition证券业务集团的负责人，并从2007年1月至2013年1月，成为公司OmniLit Acquisition管理委员会的成员。他在Virginia Military Institute获得了学士学位，并在West Virginia University College of Law获得了法学博士学位。
- James M. Jenkins has served as Birchbiomed Inc.'s lead independent director since May 2026. Mr. Jenkins is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Mr. Jenkins has served as President and Chief Executive Officer of Lakeland Industries, Inc. (Nasdaq: LAKE) since June 2024 where he has also served as Executive Chairman since August 2023. Prior to his appointment as President and Chief Executive Officer of Lakeland, Mr. Jenkins was the General Counsel and Vice President of Corporate Development for Transcat, Inc. (Nasdaq: TRNS), a provider of calibration, repair, inspection and laboratory services, where he served as Transcat's chief risk officer and advised management and the board of directors over matters of corporate governance and securities law. He also led Transcat's acquisition strategy. He joined Transcat in September 2020. Prior to joining Transcat, he was a partner at Harter Secrest & Emery LLP, a regional law firm located in New York State. His practice focused in the areas of corporate governance, and general corporate law matters, including initial and secondary public offerings, private placements, mergers and acquisitions, and securities law compliance. Mr. Jenkins joined the firm in 1989 as an associate and was elected a partner effective January 1, 1997. He is a Chambers rated attorney and served as the Chair of the firm's Securities Practice Group from 2001 to 2020 and as a member of the firm's Management Committee from January 2007 to January 2013. From 2018 until September 2020, he served as the Partner in Charge of the firm's New York City office. Mr. Jenkins holds a B.A. from Virginia Military Institute and a J.D. from West Virginia University College of Law. Mr. Jenkins currently serves on the board of directors of Lakeland Industries. Mr. Jenkins previously served on the board of directors of Mars Acquisition Corp. until its acquisition by ScanTech AI Systems Inc. (Nasdaq: STAI) and OmniLit Acquisition Corp. from September 2021 to April 2023. Mr. Jenkins previously served on the board of directors of ScanTech AI Systems Inc., was a member of its audit (Chair) and compensation committees, from December 2024 to October 2025.
- Susan Elliott
-
Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising的业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和销售推广活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。
Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising. - Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising的业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和销售推广活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。
- Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising.
- Teresa Bair
-
自2020年以来，Teresa Bair一直担任Birchbiomed Inc.的董事之一。Bair女士负责执行与监督公司管理相关的所需工作，她将投入必要的时间来执行此类工作。Bair女士目前是Kura Oncology, Inc.（纳斯达克：KURA）的首席法务官兼秘书，自2021年10月起任职。Bair女士拥有超过25年的内部和律师事务所综合经验，曾于2015年6月至2021年10月在Athenex, Inc.担任总法律顾问和行政高级副总裁，在那里她帮助领导该组织从一家私营的临床前阶段公司发展成为一家全球性的上市生物制药公司，直接为多个新药申请申请申请和美国食品和药物管理局的批准做出了贡献。此前，她曾于1999年11月至2015年6月担任Harris Beach PLLC的合伙人，就商业诉讼事宜为不同行业的商业客户提供咨询，包括《财富》500强公司。Bair女士担任布法罗大学法学院校友会的董事会成员，以及布法罗大学基金会的董事会成员。她在纽约州立大学布法罗法学院获得法学博士学位，在鲍灵格林州立大学获得行政管理学士学位。
Teresa Bair has served as one of Birchbiomed Inc.'s Directors since 2020. Ms. Bair is responsible for performing the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Bair is currently the Chief Legal Officer and Secretary of Kura Oncology, Inc. (Nasdaq: KURA), since October 2021. Ms. Bair has more than 25 years of combined in house and law firm experience, serving as General Counsel and Senior Vice President, Administration at Athenex, Inc., from June 2015 to October 2021, where she helped lead the organization through its evolution from a private, preclinical stage company to a global, publicly traded biopharmaceutical company, directly contributing to multiple new drug application filings and an U.S. Food and Drug Administration approval. Previously, she was a partner at Harris Beach PLLC from November 1999 to June 2015, advising business clients, including Fortune 500 companies, across diverse industries on commercial litigation matters. Ms. Bair serves on the Boards of Directors of the University at Buffalo Law Alumni Association, as well as the Board of Trustees of the University at Buffalo Foundation. She earned her J.D. from State University of New York at Buffalo School of Law and her B.S. in administration from Bowling Green State University. - 自2020年以来，Teresa Bair一直担任Birchbiomed Inc.的董事之一。Bair女士负责执行与监督公司管理相关的所需工作，她将投入必要的时间来执行此类工作。Bair女士目前是Kura Oncology, Inc.（纳斯达克：KURA）的首席法务官兼秘书，自2021年10月起任职。Bair女士拥有超过25年的内部和律师事务所综合经验，曾于2015年6月至2021年10月在Athenex, Inc.担任总法律顾问和行政高级副总裁，在那里她帮助领导该组织从一家私营的临床前阶段公司发展成为一家全球性的上市生物制药公司，直接为多个新药申请申请申请和美国食品和药物管理局的批准做出了贡献。此前，她曾于1999年11月至2015年6月担任Harris Beach PLLC的合伙人，就商业诉讼事宜为不同行业的商业客户提供咨询，包括《财富》500强公司。Bair女士担任布法罗大学法学院校友会的董事会成员，以及布法罗大学基金会的董事会成员。她在纽约州立大学布法罗法学院获得法学博士学位，在鲍灵格林州立大学获得行政管理学士学位。
- Teresa Bair has served as one of Birchbiomed Inc.'s Directors since 2020. Ms. Bair is responsible for performing the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Bair is currently the Chief Legal Officer and Secretary of Kura Oncology, Inc. (Nasdaq: KURA), since October 2021. Ms. Bair has more than 25 years of combined in house and law firm experience, serving as General Counsel and Senior Vice President, Administration at Athenex, Inc., from June 2015 to October 2021, where she helped lead the organization through its evolution from a private, preclinical stage company to a global, publicly traded biopharmaceutical company, directly contributing to multiple new drug application filings and an U.S. Food and Drug Administration approval. Previously, she was a partner at Harris Beach PLLC from November 1999 to June 2015, advising business clients, including Fortune 500 companies, across diverse industries on commercial litigation matters. Ms. Bair serves on the Boards of Directors of the University at Buffalo Law Alumni Association, as well as the Board of Trustees of the University at Buffalo Foundation. She earned her J.D. from State University of New York at Buffalo School of Law and her B.S. in administration from Bowling Green State University.
- Susan Elliott
-
Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和促销活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。Birchbiomed Inc.董事会认为，Elliott女士在Birchbiomed Inc.公司的广泛知识和领导经验以及她在商业、营销和公共关系方面的广泛经验使她有资格担任Birchbiomed Inc.公司的董事。
Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising. Birchbiomed Inc.'s Board believes that Ms. Elliott's extensive knowledge and leadership experience with Birchbiomed Inc.'s company and her breadth of experience with business, marketing, and public relations qualifies her to serve as a director of Birchbiomed Inc.'s Company. - Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和促销活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。Birchbiomed Inc.董事会认为，Elliott女士在Birchbiomed Inc.公司的广泛知识和领导经验以及她在商业、营销和公共关系方面的广泛经验使她有资格担任Birchbiomed Inc.公司的董事。
- Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising. Birchbiomed Inc.'s Board believes that Ms. Elliott's extensive knowledge and leadership experience with Birchbiomed Inc.'s company and her breadth of experience with business, marketing, and public relations qualifies her to serve as a director of Birchbiomed Inc.'s Company.
- Mark S. Miller
-
Mark S. Miller是联合创始人，自2015年2月20日起担任Birchbiomed Inc.的首席执行官办公室。Miller先生作为Birchbiomed Inc.首席执行官的职责是提供整体战略方向，监督高级管理层和运营，并代表Birchbiomed Inc.与关键利益相关者。根据与Carlisle Group，Inc.（“Carlisle Group”）的咨询协议，Miller先生担任Birchbiomed Inc.的全职首席执行官，Carlisle Group，Inc.是一家提供全方位服务的营销和C套房咨询公司。更多信息请参见“执行和董事薪酬”。他也是卡莱尔集团的联合创始人和董事会主席，以及Trivest Global Holdings Ltd.的董事会主席。米勒先生曾是福特汽车公司的高管，曾是福特高管团队的一员，被分配到捷豹汽车的重组和复兴中，他曾担任公司和公共事务副总裁。他还曾在Ford Aerospace、Piper Aircraft以及弗吉尼亚中心银行的百事可乐担任行政和管理职务。米勒先生是一名国家级、屡获殊荣的印刷和广播记者，曾在《华盛顿邮报》、《波士顿环球报》、赫斯特报纸、甘尼特报纸、公共广播电台（“WBJC”）和WJZ电视台担任编辑和/或高级管理职务。米勒先生两次获得普利策奖的编辑提名，是保罗·迈尔奖（密苏里大学新闻卓越最高奖项）和纽约州律师协会媒体奖的获得者。Miller先生曾担任马里兰州立学院和大学系统公共和政府事务主任，并担任陶森大学新闻学兼职教授。作为一名科学/医学作家，米勒先生是《Bad Trips》（Chelsea House Publishers，纽约）的作者，并在《约翰霍普金斯酒精研究报告》、《约翰霍普金斯动物试验替代中心期刊》、《简讯》（约翰霍普金斯卫生与公共卫生学院期刊）、美联社和路透社发表了大量文章。Miller先生是弗吉尼亚大学的荣誉毕业生，该大学艺术与科学学院的优等生，杜克大学Fuqua商学院：高管战略营销项目和密歇根大学Rackham研究生院：L.E.A.D高管领导力项目的毕业生。
Mark S. Miller is a co founder and has served as Birchbiomed Inc.'s Chief Executive Office since February 20, 2015. Mr. Miller's responsibilities as Birchbiomed Inc.'s CEO are to provide overall strategic direction, overseeing senior management and operations, and representing Birchbiomed Inc. with key stakeholders. Mr. Miller serves as Birchbiomed Inc.'s CEO on a full time basis pursuant to a consulting agreement with The Carlisle Group, Inc. (the "Carlisle Group"), a full service marketing and C suite consulting company. See "Executive and Director Compensation" for more information.He is also co founder and Board Chairman of The Carlisle Group, and Board Chairman of Trivest Global Holdings Ltd. A former executive with Ford Motor Company, Mr. Miller was part of the Ford executive team assigned to the reorganization and rejuvenation of Jaguar Cars, where he served as Vice President of Corporate and Public Affairs. He also has held executive and management positions with Ford Aerospace, Piper Aircraft, and Pepsi Cola of Central Virginia. A national, award winning print and broadcast journalist, Mr. Miller has held editorial and/or senior management positions with The Washington Post, The Boston Globe, Hearst Newspapers, Gannett Newspapers, Public Radio ("WBJC") and WJZ TV. Twice nominated by his editors for the Pulitzer Prize, Mr. Miller is the recipient of The Paul Myhre Award (The University of Missouri's highest award for journalistic excellence) and The New York State Bar Association Media Award. Mr. Miller was Director of Public and Governmental Affairs for the Maryland State College and University System and served as an adjunct Professor of Journalism at Towson University. In his capacity as a science/medical writer, Mr. Miller is the author of Bad Trips (Chelsea House Publishers, New York) and numerous articles published in The Johns Hopkins Alcohol Research Report, The Journal of The Johns Hopkins Center for Alternatives to Animal Testing, In Brief (journal of The Johns Hopkins School of Hygiene and Public Health), The Associated Press and Reuters. Mr. Miller is an honors graduate of The University of Virginia, a cum laude graduate of the University's College of Arts & Sciences, and a graduate of Duke University's Fuqua School of Business: Executive Strategic Marketing Program and The University of Michigan's Rackham Graduate School: L.E.A.D executive leadership program. - Mark S. Miller是联合创始人，自2015年2月20日起担任Birchbiomed Inc.的首席执行官办公室。Miller先生作为Birchbiomed Inc.首席执行官的职责是提供整体战略方向，监督高级管理层和运营，并代表Birchbiomed Inc.与关键利益相关者。根据与Carlisle Group，Inc.（“Carlisle Group”）的咨询协议，Miller先生担任Birchbiomed Inc.的全职首席执行官，Carlisle Group，Inc.是一家提供全方位服务的营销和C套房咨询公司。更多信息请参见“执行和董事薪酬”。他也是卡莱尔集团的联合创始人和董事会主席，以及Trivest Global Holdings Ltd.的董事会主席。米勒先生曾是福特汽车公司的高管，曾是福特高管团队的一员，被分配到捷豹汽车的重组和复兴中，他曾担任公司和公共事务副总裁。他还曾在Ford Aerospace、Piper Aircraft以及弗吉尼亚中心银行的百事可乐担任行政和管理职务。米勒先生是一名国家级、屡获殊荣的印刷和广播记者，曾在《华盛顿邮报》、《波士顿环球报》、赫斯特报纸、甘尼特报纸、公共广播电台（“WBJC”）和WJZ电视台担任编辑和/或高级管理职务。米勒先生两次获得普利策奖的编辑提名，是保罗·迈尔奖（密苏里大学新闻卓越最高奖项）和纽约州律师协会媒体奖的获得者。Miller先生曾担任马里兰州立学院和大学系统公共和政府事务主任，并担任陶森大学新闻学兼职教授。作为一名科学/医学作家，米勒先生是《Bad Trips》（Chelsea House Publishers，纽约）的作者，并在《约翰霍普金斯酒精研究报告》、《约翰霍普金斯动物试验替代中心期刊》、《简讯》（约翰霍普金斯卫生与公共卫生学院期刊）、美联社和路透社发表了大量文章。Miller先生是弗吉尼亚大学的荣誉毕业生，该大学艺术与科学学院的优等生，杜克大学Fuqua商学院：高管战略营销项目和密歇根大学Rackham研究生院：L.E.A.D高管领导力项目的毕业生。
- Mark S. Miller is a co founder and has served as Birchbiomed Inc.'s Chief Executive Office since February 20, 2015. Mr. Miller's responsibilities as Birchbiomed Inc.'s CEO are to provide overall strategic direction, overseeing senior management and operations, and representing Birchbiomed Inc. with key stakeholders. Mr. Miller serves as Birchbiomed Inc.'s CEO on a full time basis pursuant to a consulting agreement with The Carlisle Group, Inc. (the "Carlisle Group"), a full service marketing and C suite consulting company. See "Executive and Director Compensation" for more information.He is also co founder and Board Chairman of The Carlisle Group, and Board Chairman of Trivest Global Holdings Ltd. A former executive with Ford Motor Company, Mr. Miller was part of the Ford executive team assigned to the reorganization and rejuvenation of Jaguar Cars, where he served as Vice President of Corporate and Public Affairs. He also has held executive and management positions with Ford Aerospace, Piper Aircraft, and Pepsi Cola of Central Virginia. A national, award winning print and broadcast journalist, Mr. Miller has held editorial and/or senior management positions with The Washington Post, The Boston Globe, Hearst Newspapers, Gannett Newspapers, Public Radio ("WBJC") and WJZ TV. Twice nominated by his editors for the Pulitzer Prize, Mr. Miller is the recipient of The Paul Myhre Award (The University of Missouri's highest award for journalistic excellence) and The New York State Bar Association Media Award. Mr. Miller was Director of Public and Governmental Affairs for the Maryland State College and University System and served as an adjunct Professor of Journalism at Towson University. In his capacity as a science/medical writer, Mr. Miller is the author of Bad Trips (Chelsea House Publishers, New York) and numerous articles published in The Johns Hopkins Alcohol Research Report, The Journal of The Johns Hopkins Center for Alternatives to Animal Testing, In Brief (journal of The Johns Hopkins School of Hygiene and Public Health), The Associated Press and Reuters. Mr. Miller is an honors graduate of The University of Virginia, a cum laude graduate of the University's College of Arts & Sciences, and a graduate of Duke University's Fuqua School of Business: Executive Strategic Marketing Program and The University of Michigan's Rackham Graduate School: L.E.A.D executive leadership program.
- Charles N. Ellis
-
Charles N. Ellis自2019年起担任Birchbiomed Inc.的董事之一。Ellis博士负责执行与监督公司管理相关的所需工作，他将投入必要的时间来执行这些工作。Ellis博士目前是密歇根大学医学院皮肤病学名誉教授。在此之前，他曾于2008年至2018年担任密歇根大学医学院皮肤病学William B. Taylor教授。在近四十年的时间里，埃利斯博士曾担任密歇根大学皮肤病学系的多个职务，包括担任William B. Taylor教授和副主席；住院培训计划主任；以及临床研究单位主任。在指导研究单位期间，他设计并管理了数百项皮肤病学临床试验，发表了250多篇期刊文章和书籍章节。他的出版物的重要性使埃利斯博士成为全球十几位最有影响力和被引用的皮肤科医生之一。曾任多家大大小小的医药公司顾问，承担多个客座教授职务，曾任各期刊编委。获五项专利授权。他是医疗中心卓越服务部的创始人和主任。Ellis博士还是VA安娜堡医院皮肤科服务主任，在那里他继续他的教学和临床实践。埃利斯博士被任命为美国皮肤病学会荣誉会员。在密歇根大学，他获得了H. R. Johnson多元化领导力奖。在该大学的卫生系统中，埃利斯博士被公认为“医生的医生”，并被选为医学院卓越教育联盟的首届成员，并被命名为其医学教育家学院。Ellis博士以卓越的研究成绩获得了密歇根大学医学院的医学学位，并在该大学的皮肤病学系担任住院医师。Ellis博士作为世界著名皮肤科医生和教育家的广泛经验使他有资格担任主任。
Charles N. Ellis has served as one of Birchbiomed Inc.'s Directors since 2019. Dr. Ellis is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Dr. Ellis is currently Professor Emeritus of Dermatology in the University of Michigan Medical School. Prior to this he served as the William B. Taylor Professor of Dermatology at the University of Michigan Medical School from 2008 to 2018. For nearly forty years, Dr Ellis served the University of Michigan Department of Dermatology in multiple roles including as William B. Taylor Professor and Associate Chair; director of the Residency Training Program; and director of the Clinical Research Unit. While directing the Research Unit, he designed and managed hundreds of clinical trials in dermatology and published more than 250 journal articles and book chapters. The importance of his publications has made Dr. Ellis one of the dozen most influential and cited dermatologists worldwide. He has been a consultant for many large and small pharmaceutical companies, undertaken many visiting professorships, served on the editorial boards of various journals. and has been granted five patents. He was the Founder and Director of the Medical Center's Department of Service Excellence. Dr. Ellis was also Chief of the Dermatology Service at the VA Ann Arbor Hospital, where he continues his teaching and clinical practice. Dr. Ellis has been named an Honored Member of the American Academy of Dermatology. At the University of Michigan, he received the H. R. Johnson Award for Leadership in Diversity. In the University's Health System, Dr. Ellis has been recognized as a "doctor's doctor" and was chosen as an Inaugural Member of the Medical School's League of Educational Excellence and named to its Academy of Medical Educators. Dr. Ellis received his medical degree from the University of Michigan Medical School with Distinction in Research and served his residency in the University's Department of Dermatology. Dr. Ellis' breadth of experience as a world renowned dermatologist and educator qualifies him to serve as a director. - Charles N. Ellis自2019年起担任Birchbiomed Inc.的董事之一。Ellis博士负责执行与监督公司管理相关的所需工作，他将投入必要的时间来执行这些工作。Ellis博士目前是密歇根大学医学院皮肤病学名誉教授。在此之前，他曾于2008年至2018年担任密歇根大学医学院皮肤病学William B. Taylor教授。在近四十年的时间里，埃利斯博士曾担任密歇根大学皮肤病学系的多个职务，包括担任William B. Taylor教授和副主席；住院培训计划主任；以及临床研究单位主任。在指导研究单位期间，他设计并管理了数百项皮肤病学临床试验，发表了250多篇期刊文章和书籍章节。他的出版物的重要性使埃利斯博士成为全球十几位最有影响力和被引用的皮肤科医生之一。曾任多家大大小小的医药公司顾问，承担多个客座教授职务，曾任各期刊编委。获五项专利授权。他是医疗中心卓越服务部的创始人和主任。Ellis博士还是VA安娜堡医院皮肤科服务主任，在那里他继续他的教学和临床实践。埃利斯博士被任命为美国皮肤病学会荣誉会员。在密歇根大学，他获得了H. R. Johnson多元化领导力奖。在该大学的卫生系统中，埃利斯博士被公认为“医生的医生”，并被选为医学院卓越教育联盟的首届成员，并被命名为其医学教育家学院。Ellis博士以卓越的研究成绩获得了密歇根大学医学院的医学学位，并在该大学的皮肤病学系担任住院医师。Ellis博士作为世界著名皮肤科医生和教育家的广泛经验使他有资格担任主任。
- Charles N. Ellis has served as one of Birchbiomed Inc.'s Directors since 2019. Dr. Ellis is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Dr. Ellis is currently Professor Emeritus of Dermatology in the University of Michigan Medical School. Prior to this he served as the William B. Taylor Professor of Dermatology at the University of Michigan Medical School from 2008 to 2018. For nearly forty years, Dr Ellis served the University of Michigan Department of Dermatology in multiple roles including as William B. Taylor Professor and Associate Chair; director of the Residency Training Program; and director of the Clinical Research Unit. While directing the Research Unit, he designed and managed hundreds of clinical trials in dermatology and published more than 250 journal articles and book chapters. The importance of his publications has made Dr. Ellis one of the dozen most influential and cited dermatologists worldwide. He has been a consultant for many large and small pharmaceutical companies, undertaken many visiting professorships, served on the editorial boards of various journals. and has been granted five patents. He was the Founder and Director of the Medical Center's Department of Service Excellence. Dr. Ellis was also Chief of the Dermatology Service at the VA Ann Arbor Hospital, where he continues his teaching and clinical practice. Dr. Ellis has been named an Honored Member of the American Academy of Dermatology. At the University of Michigan, he received the H. R. Johnson Award for Leadership in Diversity. In the University's Health System, Dr. Ellis has been recognized as a "doctor's doctor" and was chosen as an Inaugural Member of the Medical School's League of Educational Excellence and named to its Academy of Medical Educators. Dr. Ellis received his medical degree from the University of Michigan Medical School with Distinction in Research and served his residency in the University's Department of Dermatology. Dr. Ellis' breadth of experience as a world renowned dermatologist and educator qualifies him to serve as a director.
- Joseph Sardano
-
Joseph Sardano自2018年起担任Birchbiomed Inc.的董事之一。Sardano先生负责执行与监督公司管理相关的所需工作，他将投入必要的时间来执行此类工作。Sardano先生是申舒斯医疗保健 Inc.（纳斯达克：SRTS）的共同创始人、首席执行官兼董事会主席，自2010年成立以来。Sardano先生在医疗保健行业拥有40多年的经验。从2008年到2009年，Sardano先生担任电子近距离放射治疗医疗设备公司Xoft，Inc.的首席商务官。从2005年到2008年，Sardano先生担任Molecular Imaging Ventures的管理合伙人和医疗保健顾问。从2002年到2005年，Sardano先生担任CTI Molecular Imaging和Pet Net Pharmaceuticals的全球销售和营销高级副总裁，这是一家被Siemens Medical Solutions收购的医疗保健行业成像和同位素解决方案开发商，Sardano先生于2005年担任该公司的副总裁。从1998年到2002年，Sardano先生在GE医疗系统担任功能成像的美洲销售经理。1997年至1998年，Sardano先生担任Elscint Inc.的销售和营销副总裁，该公司是医学成像解决方案的开发商和制造商，包括核医学、计算机断层磁共振成像和X射线扫描仪，其成像活动于1999年出售给GE医疗系统公司。1991年至1995年，Sardano先生担任东芝美国医疗系统的区域销售经理。Sardano先生目前还担任BioFlorida的董事会成员，该公司推广佛罗里达州的医疗保健公司和技术。Sardano先生拥有加拿大蒙特利尔Concordia大学的文学学士学位，以及麦吉尔大学管理学院的多个商业证书。
Joseph Sardano has served as one of Birchbiomed Inc.'s Directors since 2018. Mr. Sardano is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Mr. Sardano is a co founder, Chief Executive Officer and Chairman of the Board of Sensus Healthcare Inc. (Nasdaq: SRTS), since its inception in 2010. Mr. Sardano has more than 40 years of experience in the healthcare industry. From 2008 to 2009, Mr. Sardano served as Chief Commercial Officer of Xoft, Inc., an electronic brachytherapy medical device company. From 2005 to 2008, Mr. Sardano served as managing partner and healthcare consultant for Molecular Imaging Ventures. From 2002 to 2005, Mr. Sardano served as Sr. Vice President of Global Sales and Marketing of CTI Molecular Imaging and Pet Net Pharmaceuticals, a developer of imaging and isotope solutions for the healthcare industry acquired by Siemens Medical Solutions, of which Mr. Sardano served as Vice President in 2005. From 1998 to 2002, Mr. Sardano served as Americas Sales Manager for Functional Imaging at GE Medical Systems. From 1997 to 1998, Mr. Sardano served as Vice President of Sales and Marketing for Elscint Inc., a developer and manufacturer of medical imaging solutions, including nuclear medicine, computed tomography magnetic resonance imaging, and x ray scanners, the imaging activities of which were sold to GE Medical Systems in 1999. From 1991 to 1995, Mr. Sardano served as Region Sales Manager of Toshiba America Medical Systems. Mr. Sardano also currently serves as a board member for BioFlorida, which promotes Florida based healthcare companies and technologies. Mr. Sardano has a Bachelor of Arts degree from Concordia University in Montreal, Canada, as well as several Business Certificates from McGill University School of Management. - Joseph Sardano自2018年起担任Birchbiomed Inc.的董事之一。Sardano先生负责执行与监督公司管理相关的所需工作，他将投入必要的时间来执行此类工作。Sardano先生是申舒斯医疗保健 Inc.（纳斯达克：SRTS）的共同创始人、首席执行官兼董事会主席，自2010年成立以来。Sardano先生在医疗保健行业拥有40多年的经验。从2008年到2009年，Sardano先生担任电子近距离放射治疗医疗设备公司Xoft，Inc.的首席商务官。从2005年到2008年，Sardano先生担任Molecular Imaging Ventures的管理合伙人和医疗保健顾问。从2002年到2005年，Sardano先生担任CTI Molecular Imaging和Pet Net Pharmaceuticals的全球销售和营销高级副总裁，这是一家被Siemens Medical Solutions收购的医疗保健行业成像和同位素解决方案开发商，Sardano先生于2005年担任该公司的副总裁。从1998年到2002年，Sardano先生在GE医疗系统担任功能成像的美洲销售经理。1997年至1998年，Sardano先生担任Elscint Inc.的销售和营销副总裁，该公司是医学成像解决方案的开发商和制造商，包括核医学、计算机断层磁共振成像和X射线扫描仪，其成像活动于1999年出售给GE医疗系统公司。1991年至1995年，Sardano先生担任东芝美国医疗系统的区域销售经理。Sardano先生目前还担任BioFlorida的董事会成员，该公司推广佛罗里达州的医疗保健公司和技术。Sardano先生拥有加拿大蒙特利尔Concordia大学的文学学士学位，以及麦吉尔大学管理学院的多个商业证书。
- Joseph Sardano has served as one of Birchbiomed Inc.'s Directors since 2018. Mr. Sardano is responsible for performing the work required in connection with overseeing the management of the company, and he will devote such amount of time as is necessary to perform such work. Mr. Sardano is a co founder, Chief Executive Officer and Chairman of the Board of Sensus Healthcare Inc. (Nasdaq: SRTS), since its inception in 2010. Mr. Sardano has more than 40 years of experience in the healthcare industry. From 2008 to 2009, Mr. Sardano served as Chief Commercial Officer of Xoft, Inc., an electronic brachytherapy medical device company. From 2005 to 2008, Mr. Sardano served as managing partner and healthcare consultant for Molecular Imaging Ventures. From 2002 to 2005, Mr. Sardano served as Sr. Vice President of Global Sales and Marketing of CTI Molecular Imaging and Pet Net Pharmaceuticals, a developer of imaging and isotope solutions for the healthcare industry acquired by Siemens Medical Solutions, of which Mr. Sardano served as Vice President in 2005. From 1998 to 2002, Mr. Sardano served as Americas Sales Manager for Functional Imaging at GE Medical Systems. From 1997 to 1998, Mr. Sardano served as Vice President of Sales and Marketing for Elscint Inc., a developer and manufacturer of medical imaging solutions, including nuclear medicine, computed tomography magnetic resonance imaging, and x ray scanners, the imaging activities of which were sold to GE Medical Systems in 1999. From 1991 to 1995, Mr. Sardano served as Region Sales Manager of Toshiba America Medical Systems. Mr. Sardano also currently serves as a board member for BioFlorida, which promotes Florida based healthcare companies and technologies. Mr. Sardano has a Bachelor of Arts degree from Concordia University in Montreal, Canada, as well as several Business Certificates from McGill University School of Management.
高管简历
中英对照 | 中文 | 英文- Susan Elliott
Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising的业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和销售推广活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。
Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising.- Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising的业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和销售推广活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。
- Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising.
- Carlos Camozzi
Carlos Camozzi自2023年3月1日起担任Birchbiomed Inc.的首席医疗官。Camozzi博士为Birchbiomed Inc.的研发项目提供战略性医疗和临床领导。作为Birchbiomed Inc.的CMO，Camozzi博士负责监督临床战略，从早期研究到临床试验指导药物开发，并确保与监管、伦理和科学标准保持一致。根据与CRC Management Consulting GmbH（“CRC”）的咨询协议，Camozzi博士担任Birchbiomed Inc.的全职CMO。更多信息请参见“某些关系和关联交易”。Camozzi博士在医疗保健行业拥有超过40年的经验。Camozzi博士成功地领导了与美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）的数次监管互动、磋商、提交和批准，涉及多个预IND和IND、CTA和IRB/EC、孤儿药申请（ODA）和ODDs、儿科研究计划（PIP）、成功的审评方法（即优先审评、突破性疗法、加速批准、快速通道、有条件批准、特殊情况）和上市许可申请（MAA）。卓越的监管成就包括FDA批准Carbaglu用于治疗NAGS缺乏症和EMA重新评估以及西方世界首次批准基因疗法（Glybera）。他曾担任NLS Pharmaceutics医疗总监和执行委员会成员；孤儿药开发和商业化的先驱Orphan Europe（Recordati集团成员）的医疗总监、医疗事务负责人、发展项目协调员；巴塞尔大学医院分子病理学分部科学战略总监。Camozzi博士在布宜诺斯艾利斯国立大学医学院获得医学学位，在布宜诺斯艾利斯国立大学获得临床化学博士学位，并在儿科、新生儿科和神经精神病学领域获得博士学位。他还获得了阿根廷天主教大学高级国家卫生研究所临床药理学博士学位。
Carlos Camozzi has served as Birchbiomed Inc.'s Chief Medical Officer since March 1, 2023. Dr. Camozzi provides strategic medical and clinical leadership for Birchbiomed Inc.'s research and development programs. As Birchbiomed Inc.'s CMO, Dr. Camozzi oversees clinical strategy, guides drug development from early research through clinical trials, and ensures alignment with regulatory, ethical, and scientific standards. Dr. Camozzi serves as Birchbiomed Inc.'s CMO on a full time basis pursuant to a consulting agreement with CRC Management Consulting GmbH ("CRC"). See "Certain Relationships and Related Party Transactions" for more information. Dr. Camozzi has more than 40 years' experience in the healthcare industry. Dr. Camozzi has successfully led several regulatory interactions, consultations, submissions and approvals, with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), of several pre INDs and INDs, CTAs and IRBs/ECs, Orphan Drug Applications (ODA) and ODDs, Pediatric Investigational Plans (PIP), successful review approaches (i.e., priority review, breakthrough therapy, accelerated approval, fast track, conditional approval, exceptional circumstances), and Marketing Authorizations Applications (MAA). Outstanding regulatory achievements include the FDA approval of Carbaglu for the treatment of NAGS deficiency and the EMA re assessment and first ever approval of a gene therapy (Glybera) in the western world. He has served as Medical Director and member of the Executive Committee of NLS Pharmaceutics; Medical Director, Head of Medical Affairs, and Development Projects Coordinator for Orphan Europe (member of the Recordati Group), a pioneer in the development and commercialization of orphan drugs; and Scientific Strategy Director, Division of Molecular Pathology Basel University Hospital. Dr. Camozzi received his medical degree from the School of Medicine, National University of Buenos Aires, his Ph.D. in Clinical Chemistry from the National University of Buenos Aires, as well as in Pediatrics, Neonatology and Neuropsychiatry. He also received a degree as Doctor in Clinical Pharmacology from the Superior National Institute of Health, Catholic University of Argentina.- Carlos Camozzi自2023年3月1日起担任Birchbiomed Inc.的首席医疗官。Camozzi博士为Birchbiomed Inc.的研发项目提供战略性医疗和临床领导。作为Birchbiomed Inc.的CMO，Camozzi博士负责监督临床战略，从早期研究到临床试验指导药物开发，并确保与监管、伦理和科学标准保持一致。根据与CRC Management Consulting GmbH（“CRC”）的咨询协议，Camozzi博士担任Birchbiomed Inc.的全职CMO。更多信息请参见“某些关系和关联交易”。Camozzi博士在医疗保健行业拥有超过40年的经验。Camozzi博士成功地领导了与美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）的数次监管互动、磋商、提交和批准，涉及多个预IND和IND、CTA和IRB/EC、孤儿药申请（ODA）和ODDs、儿科研究计划（PIP）、成功的审评方法（即优先审评、突破性疗法、加速批准、快速通道、有条件批准、特殊情况）和上市许可申请（MAA）。卓越的监管成就包括FDA批准Carbaglu用于治疗NAGS缺乏症和EMA重新评估以及西方世界首次批准基因疗法（Glybera）。他曾担任NLS Pharmaceutics医疗总监和执行委员会成员；孤儿药开发和商业化的先驱Orphan Europe（Recordati集团成员）的医疗总监、医疗事务负责人、发展项目协调员；巴塞尔大学医院分子病理学分部科学战略总监。Camozzi博士在布宜诺斯艾利斯国立大学医学院获得医学学位，在布宜诺斯艾利斯国立大学获得临床化学博士学位，并在儿科、新生儿科和神经精神病学领域获得博士学位。他还获得了阿根廷天主教大学高级国家卫生研究所临床药理学博士学位。
- Carlos Camozzi has served as Birchbiomed Inc.'s Chief Medical Officer since March 1, 2023. Dr. Camozzi provides strategic medical and clinical leadership for Birchbiomed Inc.'s research and development programs. As Birchbiomed Inc.'s CMO, Dr. Camozzi oversees clinical strategy, guides drug development from early research through clinical trials, and ensures alignment with regulatory, ethical, and scientific standards. Dr. Camozzi serves as Birchbiomed Inc.'s CMO on a full time basis pursuant to a consulting agreement with CRC Management Consulting GmbH ("CRC"). See "Certain Relationships and Related Party Transactions" for more information. Dr. Camozzi has more than 40 years' experience in the healthcare industry. Dr. Camozzi has successfully led several regulatory interactions, consultations, submissions and approvals, with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), of several pre INDs and INDs, CTAs and IRBs/ECs, Orphan Drug Applications (ODA) and ODDs, Pediatric Investigational Plans (PIP), successful review approaches (i.e., priority review, breakthrough therapy, accelerated approval, fast track, conditional approval, exceptional circumstances), and Marketing Authorizations Applications (MAA). Outstanding regulatory achievements include the FDA approval of Carbaglu for the treatment of NAGS deficiency and the EMA re assessment and first ever approval of a gene therapy (Glybera) in the western world. He has served as Medical Director and member of the Executive Committee of NLS Pharmaceutics; Medical Director, Head of Medical Affairs, and Development Projects Coordinator for Orphan Europe (member of the Recordati Group), a pioneer in the development and commercialization of orphan drugs; and Scientific Strategy Director, Division of Molecular Pathology Basel University Hospital. Dr. Camozzi received his medical degree from the School of Medicine, National University of Buenos Aires, his Ph.D. in Clinical Chemistry from the National University of Buenos Aires, as well as in Pediatrics, Neonatology and Neuropsychiatry. He also received a degree as Doctor in Clinical Pharmacology from the Superior National Institute of Health, Catholic University of Argentina.
- Susan Elliott
Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和促销活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。Birchbiomed Inc.董事会认为，Elliott女士在Birchbiomed Inc.公司的广泛知识和领导经验以及她在商业、营销和公共关系方面的广泛经验使她有资格担任Birchbiomed Inc.公司的董事。
Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising. Birchbiomed Inc.'s Board believes that Ms. Elliott's extensive knowledge and leadership experience with Birchbiomed Inc.'s company and her breadth of experience with business, marketing, and public relations qualifies her to serve as a director of Birchbiomed Inc.'s Company.- Susan Elliott是联合创始人，自2025年9月25日起担任Birchbiomed Inc.的首席运营官，在此之前，她自2015年2月20日起担任Birchbiomed Inc.的首席营销官。Elliot女士负责监督Birchbiomed Inc.的日常运营，并将战略目标转化为有效的执行。作为首席运营官，Elliot女士在运营、质量、监管准备、财务协调和组织发展方面发挥着领导作用，确保Birchbiomed Inc.的运营高效、合规并为增长做好准备。Elliot女士根据与Elliott，Clark Communications（“ECC”）的咨询协议，担任Birchbiomed Inc.的全职首席运营官。有关更多信息，请参阅“执行和董事薪酬”。Elliott女士还自2015年2月起担任Birchbiomed Inc.的董事之一。她作为董事的职责是履行与监督公司管理相关的所需工作，她将投入必要的时间来执行这些工作。Elliott女士自ECC于1989年成立（成立于1992年）以来一直是ECC的所有者/负责人和创始人，在那里她为许多知名公司制定了战略沟通并策划了产品发布，包括日产、日产基金会、英菲尼迪、丰田、克莱斯勒、宝马、三菱、本田、捷豹北美、加拿大国际车展和Green Living Enterprises。Elliott女士是C Suite高管在营销战略/实施、产品植入和媒体关系方面值得信赖的顾问。Elliott女士还负责为公关公司Bob Thomas & Associates建立和指导加拿大业务；担任Chiat/Day/Mojo Advertising业务发展/公关副总裁；负责Mazda Canada Inc.的商品销售（处理公司的营销、广告、公关和促销活动）；并担任英国Leyland/Jaguar、Burmah Castrol和Starword Communications的高级客户管理。作为加拿大汽车记者协会（“AJAC”）的长期成员，艾略特女士被授予该组织的最高荣誉，即托尼口号奖。Elliott女士也是Trivest的董事会成员。埃利奥特女士就读于多伦多的瑞尔森学院，在那里她学习了商业管理、市场营销和广告。Birchbiomed Inc.董事会认为，Elliott女士在Birchbiomed Inc.公司的广泛知识和领导经验以及她在商业、营销和公共关系方面的广泛经验使她有资格担任Birchbiomed Inc.公司的董事。
- Susan Elliott is a co founder and has served as Birchbiomed Inc.'s Chief Operating Officer since September 25, 2025, prior to which she served as Birchbiomed Inc.'s Chief Marketing Officer since February 20, 2015. Ms. Elliot is responsible for overseeing Birchbiomed Inc.'s day to day operations and translating strategic objectives into effective execution. As COO Ms. Elliot plays a hands on leadership role across operations, quality, regulatory readiness, finance coordination, and organizational development, ensuring Birchbiomed Inc.'s operations run efficiently, compliantly, and are positioned for growth. Ms. Elliot serves as Birchbiomed Inc.'s COO on a full time basis pursuant to a consulting agreement with Elliott, Clark Communications ("ECC"). See "Executive and Director Compensation" for more information. Ms. Elliott has also served as one of Birchbiomed Inc.'s directors since February 2015. Her responsibilities as a director are to perform the work required in connection with overseeing the management of the company, and she will devote such amount of time as is necessary to perform such work. Ms. Elliott is the owner/principal and founder of ECC since its inception in 1989 (incorporated in 1992), where she has developed strategic communications and orchestrated product launches for many prominent companies, including Nissan, The Nissan Foundation, Infiniti, Toyota, Chrysler, BMW, Mitsubishi, Honda, Jaguar North America, The Canadian International Auto Show and Green Living Enterprises. Ms. Elliott was a trusted advisor to C Suite executives on marketing strategy/implementation, product placement and media relations. Ms. Elliott was also in charge of establishing and directing the Canadian operations for public relations firm Bob Thomas & Associates; served as Vice President, Business Development/PR for Chiat/Day/Mojo Advertising; was in charge of merchandising for Mazda Canada Inc. (handling the company's marketing, advertising, public relations, and sales promotion activities); and served as Senior Account Management for British Leyland/Jaguar, Burmah Castrol, and Starword Communications. A long time member of the Automotive Journalists Association of Canada ("AJAC"), Ms. Elliott was awarded the group's highest honor, the Tony Sloga Award. Ms. Elliott is also a member of the board of Trivest. Ms. Elliott attended Ryerson College in Toronto, where she studied Business Management, Marketing and Advertising. Birchbiomed Inc.'s Board believes that Ms. Elliott's extensive knowledge and leadership experience with Birchbiomed Inc.'s company and her breadth of experience with business, marketing, and public relations qualifies her to serve as a director of Birchbiomed Inc.'s Company.
- Mark S. Miller
Mark S. Miller是联合创始人，自2015年2月20日起担任Birchbiomed Inc.的首席执行官办公室。Miller先生作为Birchbiomed Inc.首席执行官的职责是提供整体战略方向，监督高级管理层和运营，并代表Birchbiomed Inc.与关键利益相关者。根据与Carlisle Group，Inc.（“Carlisle Group”）的咨询协议，Miller先生担任Birchbiomed Inc.的全职首席执行官，Carlisle Group，Inc.是一家提供全方位服务的营销和C套房咨询公司。更多信息请参见“执行和董事薪酬”。他也是卡莱尔集团的联合创始人和董事会主席，以及Trivest Global Holdings Ltd.的董事会主席。米勒先生曾是福特汽车公司的高管，曾是福特高管团队的一员，被分配到捷豹汽车的重组和复兴中，他曾担任公司和公共事务副总裁。他还曾在Ford Aerospace、Piper Aircraft以及弗吉尼亚中心银行的百事可乐担任行政和管理职务。米勒先生是一名国家级、屡获殊荣的印刷和广播记者，曾在《华盛顿邮报》、《波士顿环球报》、赫斯特报纸、甘尼特报纸、公共广播电台（“WBJC”）和WJZ电视台担任编辑和/或高级管理职务。米勒先生两次获得普利策奖的编辑提名，是保罗·迈尔奖（密苏里大学新闻卓越最高奖项）和纽约州律师协会媒体奖的获得者。Miller先生曾担任马里兰州立学院和大学系统公共和政府事务主任，并担任陶森大学新闻学兼职教授。作为一名科学/医学作家，米勒先生是《Bad Trips》（Chelsea House Publishers，纽约）的作者，并在《约翰霍普金斯酒精研究报告》、《约翰霍普金斯动物试验替代中心期刊》、《简讯》（约翰霍普金斯卫生与公共卫生学院期刊）、美联社和路透社发表了大量文章。Miller先生是弗吉尼亚大学的荣誉毕业生，该大学艺术与科学学院的优等生，杜克大学Fuqua商学院：高管战略营销项目和密歇根大学Rackham研究生院：L.E.A.D高管领导力项目的毕业生。
Mark S. Miller is a co founder and has served as Birchbiomed Inc.'s Chief Executive Office since February 20, 2015. Mr. Miller's responsibilities as Birchbiomed Inc.'s CEO are to provide overall strategic direction, overseeing senior management and operations, and representing Birchbiomed Inc. with key stakeholders. Mr. Miller serves as Birchbiomed Inc.'s CEO on a full time basis pursuant to a consulting agreement with The Carlisle Group, Inc. (the "Carlisle Group"), a full service marketing and C suite consulting company. See "Executive and Director Compensation" for more information.He is also co founder and Board Chairman of The Carlisle Group, and Board Chairman of Trivest Global Holdings Ltd. A former executive with Ford Motor Company, Mr. Miller was part of the Ford executive team assigned to the reorganization and rejuvenation of Jaguar Cars, where he served as Vice President of Corporate and Public Affairs. He also has held executive and management positions with Ford Aerospace, Piper Aircraft, and Pepsi Cola of Central Virginia. A national, award winning print and broadcast journalist, Mr. Miller has held editorial and/or senior management positions with The Washington Post, The Boston Globe, Hearst Newspapers, Gannett Newspapers, Public Radio ("WBJC") and WJZ TV. Twice nominated by his editors for the Pulitzer Prize, Mr. Miller is the recipient of The Paul Myhre Award (The University of Missouri's highest award for journalistic excellence) and The New York State Bar Association Media Award. Mr. Miller was Director of Public and Governmental Affairs for the Maryland State College and University System and served as an adjunct Professor of Journalism at Towson University. In his capacity as a science/medical writer, Mr. Miller is the author of Bad Trips (Chelsea House Publishers, New York) and numerous articles published in The Johns Hopkins Alcohol Research Report, The Journal of The Johns Hopkins Center for Alternatives to Animal Testing, In Brief (journal of The Johns Hopkins School of Hygiene and Public Health), The Associated Press and Reuters. Mr. Miller is an honors graduate of The University of Virginia, a cum laude graduate of the University's College of Arts & Sciences, and a graduate of Duke University's Fuqua School of Business: Executive Strategic Marketing Program and The University of Michigan's Rackham Graduate School: L.E.A.D executive leadership program.- Mark S. Miller是联合创始人，自2015年2月20日起担任Birchbiomed Inc.的首席执行官办公室。Miller先生作为Birchbiomed Inc.首席执行官的职责是提供整体战略方向，监督高级管理层和运营，并代表Birchbiomed Inc.与关键利益相关者。根据与Carlisle Group，Inc.（“Carlisle Group”）的咨询协议，Miller先生担任Birchbiomed Inc.的全职首席执行官，Carlisle Group，Inc.是一家提供全方位服务的营销和C套房咨询公司。更多信息请参见“执行和董事薪酬”。他也是卡莱尔集团的联合创始人和董事会主席，以及Trivest Global Holdings Ltd.的董事会主席。米勒先生曾是福特汽车公司的高管，曾是福特高管团队的一员，被分配到捷豹汽车的重组和复兴中，他曾担任公司和公共事务副总裁。他还曾在Ford Aerospace、Piper Aircraft以及弗吉尼亚中心银行的百事可乐担任行政和管理职务。米勒先生是一名国家级、屡获殊荣的印刷和广播记者，曾在《华盛顿邮报》、《波士顿环球报》、赫斯特报纸、甘尼特报纸、公共广播电台（“WBJC”）和WJZ电视台担任编辑和/或高级管理职务。米勒先生两次获得普利策奖的编辑提名，是保罗·迈尔奖（密苏里大学新闻卓越最高奖项）和纽约州律师协会媒体奖的获得者。Miller先生曾担任马里兰州立学院和大学系统公共和政府事务主任，并担任陶森大学新闻学兼职教授。作为一名科学/医学作家，米勒先生是《Bad Trips》（Chelsea House Publishers，纽约）的作者，并在《约翰霍普金斯酒精研究报告》、《约翰霍普金斯动物试验替代中心期刊》、《简讯》（约翰霍普金斯卫生与公共卫生学院期刊）、美联社和路透社发表了大量文章。Miller先生是弗吉尼亚大学的荣誉毕业生，该大学艺术与科学学院的优等生，杜克大学Fuqua商学院：高管战略营销项目和密歇根大学Rackham研究生院：L.E.A.D高管领导力项目的毕业生。
- Mark S. Miller is a co founder and has served as Birchbiomed Inc.'s Chief Executive Office since February 20, 2015. Mr. Miller's responsibilities as Birchbiomed Inc.'s CEO are to provide overall strategic direction, overseeing senior management and operations, and representing Birchbiomed Inc. with key stakeholders. Mr. Miller serves as Birchbiomed Inc.'s CEO on a full time basis pursuant to a consulting agreement with The Carlisle Group, Inc. (the "Carlisle Group"), a full service marketing and C suite consulting company. See "Executive and Director Compensation" for more information.He is also co founder and Board Chairman of The Carlisle Group, and Board Chairman of Trivest Global Holdings Ltd. A former executive with Ford Motor Company, Mr. Miller was part of the Ford executive team assigned to the reorganization and rejuvenation of Jaguar Cars, where he served as Vice President of Corporate and Public Affairs. He also has held executive and management positions with Ford Aerospace, Piper Aircraft, and Pepsi Cola of Central Virginia. A national, award winning print and broadcast journalist, Mr. Miller has held editorial and/or senior management positions with The Washington Post, The Boston Globe, Hearst Newspapers, Gannett Newspapers, Public Radio ("WBJC") and WJZ TV. Twice nominated by his editors for the Pulitzer Prize, Mr. Miller is the recipient of The Paul Myhre Award (The University of Missouri's highest award for journalistic excellence) and The New York State Bar Association Media Award. Mr. Miller was Director of Public and Governmental Affairs for the Maryland State College and University System and served as an adjunct Professor of Journalism at Towson University. In his capacity as a science/medical writer, Mr. Miller is the author of Bad Trips (Chelsea House Publishers, New York) and numerous articles published in The Johns Hopkins Alcohol Research Report, The Journal of The Johns Hopkins Center for Alternatives to Animal Testing, In Brief (journal of The Johns Hopkins School of Hygiene and Public Health), The Associated Press and Reuters. Mr. Miller is an honors graduate of The University of Virginia, a cum laude graduate of the University's College of Arts & Sciences, and a graduate of Duke University's Fuqua School of Business: Executive Strategic Marketing Program and The University of Michigan's Rackham Graduate School: L.E.A.D executive leadership program.
- Jon S. Verbeck
Jon S. Verbeck自2019年起担任Birchbiomed Inc.的首席财务官。Verbeck先生负责监督Birchbiomed Inc.的财务战略、运营和合规，以支持小型生物技术环境中的可持续增长和创新。作为首席财务官，Verbeck先生负责管理财务规划、预算编制、现金流和报告，同时确保有效使用资本并与监管要求保持一致。作为执行团队的一员，Verbeck先生与领导层密切合作，支持战略决策、筹款活动和长期价值创造。根据与Verbeck Associates，LLC（“Verbeck Associates”）的咨询协议，Verbeck先生担任Birchbiomed Inc.的全职首席财务官，Verbeck Associates，LLC（“Verbeck Associates”）是他于2006年创立的一家精品商业咨询公司。有关更多信息，请参阅“执行和董事薪酬”。在此之前，Verbeck先生一直担任Verbeck Associates的董事总经理。韦贝克先生的职业生涯始于毕马威，在审计和税务部门都有工作。Verbeck先生在其整个职业生涯中担任过多个财务管理和CFO职位，负责业务的各个方面，包括战略制定、销售管理、采购、生产运营、IT、行政和财务。Verbeck先生拥有雪城大学会计学学士学位，是一名注册会计师，获得纽约州许可。他是纽约注册会计师协会会员，美国注册会计师协会会员。
Jon S. Verbeck has served as Birchbiomed Inc.'s Chief Financial Officer since 2019. Mr. Verbeck is responsible for overseeing Birchbiomed Inc.'s financial strategy, operations, and compliance to support sustainable growth and innovation in a small biotech environment. As CFO, Mr. Verbeck manages financial planning, budgeting, cash flow, and reporting, while ensuring effective use of capital and alignment with regulatory requirements. As a member of the executive team, Mr. Verbeck partners closely with leadership to support strategic decision making, fundraising activities, and long term value creation. Mr. Verbeck serves as Birchbiomed Inc.'s CFO on a full time basis pursuant to a consulting agreement with Verbeck Associates, LLC ("Verbeck Associates"), a boutique business advisory firm he founded in 2006. See "Executive and Director Compensation" for more information. Prior to this, Mr. Verbeck has served as the Managing Director of Verbeck Associates. Mr. Verbeck began his career at KPMG, working on both the audit and tax staff. Mr. Verbeck has held multiple financial management and CFO positions throughout his career with responsibility for all aspects of the business including strategy development, sales management, purchasing, production operations, IT, administration, and finance. Mr. Verbeck holds a BS in Accounting from Syracuse University and is a Certified Public Accountant, licensed by the State of New York. He is a member of the New York Society of Certified Public Accountants, and the American Institute of Certified Public Accountants.- Jon S. Verbeck自2019年起担任Birchbiomed Inc.的首席财务官。Verbeck先生负责监督Birchbiomed Inc.的财务战略、运营和合规，以支持小型生物技术环境中的可持续增长和创新。作为首席财务官，Verbeck先生负责管理财务规划、预算编制、现金流和报告，同时确保有效使用资本并与监管要求保持一致。作为执行团队的一员，Verbeck先生与领导层密切合作，支持战略决策、筹款活动和长期价值创造。根据与Verbeck Associates，LLC（“Verbeck Associates”）的咨询协议，Verbeck先生担任Birchbiomed Inc.的全职首席财务官，Verbeck Associates，LLC（“Verbeck Associates”）是他于2006年创立的一家精品商业咨询公司。有关更多信息，请参阅“执行和董事薪酬”。在此之前，Verbeck先生一直担任Verbeck Associates的董事总经理。韦贝克先生的职业生涯始于毕马威，在审计和税务部门都有工作。Verbeck先生在其整个职业生涯中担任过多个财务管理和CFO职位，负责业务的各个方面，包括战略制定、销售管理、采购、生产运营、IT、行政和财务。Verbeck先生拥有雪城大学会计学学士学位，是一名注册会计师，获得纽约州许可。他是纽约注册会计师协会会员，美国注册会计师协会会员。
- Jon S. Verbeck has served as Birchbiomed Inc.'s Chief Financial Officer since 2019. Mr. Verbeck is responsible for overseeing Birchbiomed Inc.'s financial strategy, operations, and compliance to support sustainable growth and innovation in a small biotech environment. As CFO, Mr. Verbeck manages financial planning, budgeting, cash flow, and reporting, while ensuring effective use of capital and alignment with regulatory requirements. As a member of the executive team, Mr. Verbeck partners closely with leadership to support strategic decision making, fundraising activities, and long term value creation. Mr. Verbeck serves as Birchbiomed Inc.'s CFO on a full time basis pursuant to a consulting agreement with Verbeck Associates, LLC ("Verbeck Associates"), a boutique business advisory firm he founded in 2006. See "Executive and Director Compensation" for more information. Prior to this, Mr. Verbeck has served as the Managing Director of Verbeck Associates. Mr. Verbeck began his career at KPMG, working on both the audit and tax staff. Mr. Verbeck has held multiple financial management and CFO positions throughout his career with responsibility for all aspects of the business including strategy development, sales management, purchasing, production operations, IT, administration, and finance. Mr. Verbeck holds a BS in Accounting from Syracuse University and is a Certified Public Accountant, licensed by the State of New York. He is a member of the New York Society of Certified Public Accountants, and the American Institute of Certified Public Accountants.